Brokerages forecast that Reata Pharmaceuticals (NASDAQ:RETA) will report earnings per share (EPS) of ($0.75) for the current quarter, Zacks reports. Four analysts have issued estimates for Reata Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.86) and the highest estimate coming in at ($0.63). Reata Pharmaceuticals posted earnings per share of ($0.52) in the same quarter last year, which indicates a negative year over year growth rate of 44.2%. The company is expected to issue its next quarterly earnings results on Monday, August 13th.
According to Zacks, analysts expect that Reata Pharmaceuticals will report full year earnings of ($2.14) per share for the current financial year, with EPS estimates ranging from ($2.58) to ($1.83). For the next fiscal year, analysts forecast that the company will post earnings of ($2.97) per share, with EPS estimates ranging from ($3.82) to ($2.15). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Reata Pharmaceuticals.
Get Reata Pharmaceuticals alerts:
Reata Pharmaceuticals (NASDAQ:RETA) last announced its earnings results on Tuesday, May 8th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.76. The company had revenue of $32.39 million for the quarter, compared to the consensus estimate of $10.21 million.
Several research analysts recently issued reports on the company. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. BidaskClub raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 9th. ValuEngine raised Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Cowen reaffirmed a “hold” rating on shares of Reata Pharmaceuticals in a research report on Monday, April 9th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $54.71.
Hedge funds have recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new position in shares of Reata Pharmaceuticals in the 4th quarter worth about $127,000. DekaBank Deutsche Girozentrale bought a new position in shares of Reata Pharmaceuticals in the 1st quarter worth about $152,000. Goldman Sachs Group Inc. bought a new position in shares of Reata Pharmaceuticals in the 4th quarter worth about $307,000. Virtus Fund Advisers LLC bought a new position in shares of Reata Pharmaceuticals in the 4th quarter worth about $394,000. Finally, UBS Group AG raised its position in shares of Reata Pharmaceuticals by 473.6% in the 1st quarter. UBS Group AG now owns 19,933 shares of the company’s stock worth $409,000 after acquiring an additional 16,458 shares in the last quarter. 49.10% of the stock is owned by hedge funds and other institutional investors.
Reata Pharmaceuticals traded down $0.58, hitting $31.55, during trading hours on Friday, Marketbeat reports. 160,339 shares of the company were exchanged, compared to its average volume of 205,599. The firm has a market cap of $837.45 million, a P/E ratio of -15.85 and a beta of 0.10. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of -0.12. Reata Pharmaceuticals has a one year low of $19.31 and a one year high of $40.88.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com